Ohsu Knight Cancer Institute

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: -

Market Cap: -

Website: http://www.ohsu.edu/knight-cancer-institute

Clinical Trials

Aprepitant in Preventing Nausea and Vomiting in Patients Who Are Undergoing a Stem Cell Transplant

Not Applicable

Completed

Conditions: Cancer

Interventions: Drug: dexamethasone
Drug: aprepitant
Drug: ondansetron
Drug: placebo

First Posted Date: 2005-11-04

Last Posted Date: 2017-05-09

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 40

Registration Number: NCT00248547

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer

Phase 1

Completed

Conditions: Chronic Myeloproliferative Disorders
Leukemia
Lymphoma
Multiple Myeloma and Plasma Cell Neoplasm
Myelodysplastic Syndromes
Precancerous Condition
Myelodysplastic/Myeloproliferative Neoplasms

Interventions: Biological: therapeutic allogeneic lymphocytes
Drug: busulfan
Drug: cyclosporine
Drug: fludarabine phosphate
Drug: mycophenolate mofetil
Procedure: peripheral blood stem cell transplantation
Radiation: Total Body Irradiation (TBI)
Drug: Granulocyte colony-stimulating factor (G-CSF)
Drug: Phenytoin
Drug: Methotrexate

First Posted Date: 2005-10-27

Last Posted Date: 2017-09-27

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 147

Registration Number: NCT00245037

Locations: 🇺🇸
Knight Cancer Institute at Oregon Health and Science University, Portland, Oregon, United States

Hormone Therapy With or Without Squalamine Lactate in Treating Patients Who Are Undergoing a Radical Prostatectomy for Locally Advanced Prostate Cancer

Phase 2

Withdrawn

Conditions: Prostate Cancer

First Posted Date: 2005-10-27

Last Posted Date: 2012-05-28

Lead Sponsor: OHSU Knight Cancer Institute

Registration Number: NCT00244920

Acupuncture in Treating Hot Flashes in Patients With Prostate Cancer

Not Applicable

Terminated

Conditions: Fatigue
Hot Flashes
Prostate Cancer

First Posted Date: 2005-10-27

Last Posted Date: 2017-04-28

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 22

Registration Number: NCT00244894

Locations: 🇺🇸
Portland VA Medical Center, Portland, Oregon, United States
🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

Imatinib Mesylate in Treating Patients With Myelofibrosis

Phase 2

Terminated

Conditions: Chronic Myeloproliferative Disorders

First Posted Date: 2005-10-27

Last Posted Date: 2012-01-13

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 10

Registration Number: NCT00245128

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

Flu/TBI in Treating Patients Not Responding to Previous Hormone Therapy

Phase 2

Withdrawn

Conditions: Prostate Cancer

Interventions: Other: Nonmyeloablative stem cell conditioning regimen

First Posted Date: 2005-10-21

Last Posted Date: 2012-06-01

Lead Sponsor: OHSU Knight Cancer Institute

Registration Number: NCT00242931

Fludarabine and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Metastatic Kidney Cancer That Cannot Be Removed By Surgery

Phase 2

Terminated

Conditions: Kidney Cancer

First Posted Date: 2005-10-21

Last Posted Date: 2012-05-28

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 1

Registration Number: NCT00243009

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

Acetylcysteine, Mannitol, Combination Chemotherapy, and Sodium Thiosulfate in Treating Children With Malignant Brain Tumors

Phase 1

Terminated

Conditions: Bone Marrow Suppression
Brain and Central Nervous System Tumors
Drug/Agent Toxicity by Tissue/Organ
Long-term Effects Secondary to Cancer Therapy in Children

First Posted Date: 2005-10-13

Last Posted Date: 2017-04-21

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 2

Registration Number: NCT00238173

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

Busulfan, Melphalan, and Thiotepa in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Hodgkin's or Non-Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Lymphoma

Interventions: Biological: filgrastim
Drug: busulfan
Drug: melphalan
Drug: thiotepa
Procedure: bone marrow ablation with stem cell support
Procedure: peripheral blood stem cell transplantation

First Posted Date: 2005-10-13

Last Posted Date: 2017-09-27

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 37

Registration Number: NCT00238433

Locations: 🇺🇸
Knight Cancer Institute at Oregon Health and Science University, Portland, Oregon, United States

Voriconazole and Caspofungin Acetate in Treating Invasive Fungal Infections in Patients With Weakened Immune Systems

Phase 2

Terminated

Conditions: Infection
Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: caspofungin acetate
Drug: voriconazole

First Posted Date: 2005-10-13

Last Posted Date: 2011-12-19

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 13

Registration Number: NCT00238355

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy